Page last updated: 2024-12-06

triheptanoin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Triheptanoin is a medium-chain triglyceride (MCT) that is being investigated as a potential treatment for various metabolic disorders, including obesity, diabetes, and fatty liver disease. It is a synthetic compound, created by chemically combining glycerol with heptanoic acid. The molecule is broken down and absorbed more efficiently than long-chain triglycerides, providing a readily available energy source. Triheptanoin has been shown to improve insulin sensitivity, reduce fat accumulation, and enhance satiety. Research focuses on its potential to alleviate symptoms of metabolic diseases and improve overall metabolic health. '

Cross-References

ID SourceID
PubMed CID69286
CHEMBL ID4297585
SCHEMBL ID525618
MeSH IDM0524318

Synonyms (70)

Synonym
LS-15081
glyceryl triheptanoate
620-67-7
heptanoic acid, 1,2,3-propanetriyl ester
triheptylin
glycerol triheptanoate
brn 1807724
einecs 210-647-2
trienanthoin
triheptanoic glyceride
triheptanoin
propane-1,2,3-triyl trisheptanoate
trioenanthoin
glycerol trienanthate, >=94%
1,2,3-propanetriyl triheptanoate
2,3-di(heptanoyloxy)propyl heptanoate
glyceroltriheptanoate
2p6o7cfw5k ,
lanol 37t
dermofeel tc 7
heptanoic acid, 1,1',1''-(1,2,3-propanetriyl) ester
triheptanoin [usan]
heptanoin, tri-
ec 210-647-2
3-02-00-00769 (beilstein handbook reference)
unii-2p6o7cfw5k
ux007
dub thg
triheptanoin [orange book]
triheptanoin [mi]
dojolvi
triheptanoin [who-dd]
ux-007
triheptanoin [inci]
lanol 37 t
radiamuls 2375
propane-1,2,3-triyl triheptanoate
triheptanoin [inn]
dermofeel tc-7
glycerol trienanthate
SCHEMBL525618
W-109093
AKOS027320524
DB11677
FT-0757070
DTXSID40862306
ind106011; ux007
mfcd00042910
1r,2s-(-)-norephedrinehydrochloride
dojolvi (tn)
triheptanoin (usan)
D11465
Q414576
CHEMBL4297585
ind 106011
ind-106011
ind106011
ux 007
propane-1,2,3-triyltriheptanoate
gtpl11431
A868568
CS-W013852
EN300-19627495
1,3-bis(heptanoyloxy)propan-2-yl heptanoate
HY-W013136
heptanoin, tri-(6ci,7ci,8ci)
triheptanoinum
triheptanoina
triheptanoine
SY125872

Research Excerpts

Overview

Triheptanoin is an odd-carbon, medium-chain triglyceride consisting of three fatty acids with seven carbons each on a glycerol backbone. It was designed to replenish mitochondrial metabolic deficits and restore energy homeostasis.

ExcerptReferenceRelevance
"Triheptanoin is a synthetic medium-odd chain triglyceride, produced using a GMP-compliant process, which was designed to replenish mitochondrial metabolic deficits and restore energy homeostasis."( Response to triheptanoin therapy in critically ill patients with LC-FAOD: Report of patients treated through an expanded access program.
Bedrosian, CL; Enns, GM; Lu, X; Marsden, D; Rahman, S; Ramirez, AN; Ray, K; Reineking, B; Vockley, J, 2022
)
1.82
"Triheptanoin is an odd-carbon, medium-chain triglyceride consisting of three fatty acids with seven carbons each on a glycerol backbone, indicated for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD). "( Population Pharmacokinetics of Heptanoate in Healthy Subjects and Patients With Long-Chain Fatty Acid Oxidation Disorders Treated With Triheptanoin.
Gosselin, NH; Jomphe, C; Lee, SK; McKeever, K; Putnam, W, 2022
)
2.37
"Triheptanoin is an odd-carbon, medium chain triglyceride (that is an anaplerotic substrate of calories and fatty acids) for treating pediatric and adult patients with LC-FAODs."( Triheptanoin for the treatment of long-chain fatty acid oxidation disorders: Final results of an open-label, long-term extension study.
Berry, G; Burton, BK; Chapman, KA; Grunewald, S; Longo, N; Lu, X; Murphy, E; Phillips, J; Pisani, L; Rahman, S; Ramirez, AN; Ray, K; Reineking, B; Sanchez-Valle, A; Tanpaiboon, P; Vockley, J, 2023
)
3.07
"Triheptanoin is a highly purified, 7-carbon chain triglyceride approved in the United States as a source of calories and fatty acids for treatment of pediatric and adult patients with molecularly confirmed LC-FAOD."( Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study.
Berry, G; Burton, B; Cataldo, J; Chapman, K; Grunewald, S; Longo, N; Lu, X; Murphy, E; Phillips, J; Sanchez-Valle, A; Tanpaiboon, P; Vockley, J, 2021
)
1.73
"Triheptanoin is a triglyceride oil that is broken down to acetyl-coenzyme A (CoA) and propionyl-CoA, which replenishes deficient tricarboxylic acid cycle intermediates."( Tutorial: Triheptanoin and Nutrition Management for Treatment of Long-Chain Fatty Acid Oxidation Disorders.
Chang, IJ; Gunnarson, M; Hahn, S; Lam, C; McKean, KN; Merritt, JL; Norris, MK; Scott, AI; Sullivan, S; Sun, A; Thies, JM, 2021
)
1.75
"Triheptanoin appears to be a safe and beneficial treatment option in LC-FAOD."( Long-term experience with triheptanoin in 12 Austrian patients with long-chain fatty acid oxidation disorders.
Hufgard-Leitner, M; Jörg-Streller, M; Karall, D; Konstantopoulou, V; Scholl-Bürgi, S; Spenger, J; Stock, K; Zöggeler, T, 2021
)
1.64
"Triheptanoin is an odd-carbon, medium-chain triglyceride consisting of 3 fatty acids with 7 carbons each on a glycerol backbone developed to treat adult and pediatric patients with LC-FAODs."( The Pharmacokinetics of Triheptanoin and Its Metabolites in Healthy Subjects and Patients With Long-Chain Fatty Acid Oxidation Disorders.
Gupta, M; Lee, SK; McKeever, K; Shi, J, 2021
)
1.65
"Triheptanoin appears to be a promising effective treatment for SCEH Deficiency."( Exploring triheptanoin as treatment for short chain enoyl CoA hydratase deficiency.
Brandabur, M; Brodlie, S; De Vivo, DC; Engelstad, K; Koenigsberger, D; Salazar, R; Stackowtiz, E, 2021
)
1.75
"Triheptanoin is an anaplerotic treatment designed to improve energy generation via the Krebs cycle."( A pilot study of add-on oral triheptanoin treatment for children with medically refractory epilepsy.
Barwick, K; Borges, K; Calvert, S; Ni Tan, K; Par, M, 2018
)
1.49
"Triheptanoin is a triglyceride of C7 fatty acids."( Unsuccessful treatment of severe pyruvate carboxylase deficiency with triheptanoin.
Breen, C; Heptinstall, L; Jones, SA; Morris, AA; Scott, CA; Walter, JH; White, FJ, 2014
)
1.36
"Triheptanoin is a medium odd-chain fatty acid."( UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24weeks of treatment.
Berry, GT; Bowden, A; Burton, B; Cataldo, J; Grunewald, S; Humphrey, R; Kakkis, E; Longo, N; Marsden, DL; Mayhew, J; Murphy, E; Phillips, J; Sanchez-Valle, A; Tanpaiboon, P; Vockley, J; Zhang, L, 2017
)
1.18
"The triheptanoin diet seems to be an effective therapy for adult-onset carnitine palmitoyltransferase II deficiency."( Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy.
Brunengraber, H; Garritson, BK; Roe, CR; Roe, DS; Wallace, M; Yang, BZ, 2008
)
0.9
"Triheptanoin is a triglyceride containing heptanoate, an odd-chained medium fatty acid that is metabolized to produce propionyl-CoA and subsequently C4 intermediates of the citric acid cycle and therefore capable of anaplerosis. "( Triheptanoin reduces seizure susceptibility in a syndrome-specific mouse model of generalized epilepsy.
Borges, K; Kim, TH; Petrou, S; Reid, CA, 2013
)
3.28

Effects

A triheptanoin-rich diet has anaplerotic effects because heptanoate metabolism yields succinate which delivers substrates to the Krebs cycle. Oral triheaptanoin has recently been discovered to be reproducibly anticonvulsant in acute and chronic mouse seizures models.

ExcerptReferenceRelevance
"Triheptanoin has also been investigated for use as a treatment in a range of other metabolic disorders or other diseases where energy deficiency is implicated."( Triheptanoin: First Approval.
Shirley, M, 2020
)
2.72
"A triheptanoin-rich diet has anaplerotic effects because heptanoate metabolism yields succinate which delivers substrates to the Krebs cycle."( Reduced severity of ischemic stroke and improvement of mitochondrial function after dietary treatment with the anaplerotic substance triheptanoin.
Klein, J; Koch, K; Schwarzkopf, TM, 2015
)
1.18
"Oral triheptanoin has recently been discovered to be reproducibly anticonvulsant in acute and chronic mouse seizures models."( Triheptanoin--a medium chain triglyceride with odd chain fatty acids: a new anaplerotic anticonvulsant treatment?
Borges, K; Sonnewald, U, 2012
)
2.28

Treatment

Treatment with triheptanoin resulted in a 90% clinical improvement in non-epileptic paroxysmal manifestations and a normalised brain bioenergetics profile. Treatment had minimal impact on systemic metabolism and brain amyloidosis as well as tauopathy.

ExcerptReferenceRelevance
"Triheptanoin treatment had minimal impact on systemic metabolism and brain amyloidosis as well as tauopathy while attenuating brain ATP deficiency and mitochondrial dysfunction including respiration and redox balance in 5×FAD mice. "( Triheptanoin Mitigates Brain ATP Depletion and Mitochondrial Dysfunction in a Mouse Model of Alzheimer's Disease.
Du, H; Guo, L; Pascual, JM; Sun, H; Tandon, N; Tian, J; Wang, L; Yuan, X, 2020
)
3.44
"Treatment with triheptanoin, a synthetic seven-carbon fatty acid triglyceride compound with an anaplerotic effect, seems beneficial, but clinical experience is limited."( Long-term experience with triheptanoin in 12 Austrian patients with long-chain fatty acid oxidation disorders.
Hufgard-Leitner, M; Jörg-Streller, M; Karall, D; Konstantopoulou, V; Scholl-Bürgi, S; Spenger, J; Stock, K; Zöggeler, T, 2021
)
1.26
"Treatment with triheptanoin at the protocol-specified dose decreased the rate of MCEs in patients with LC-FAOD independently from other dietary changes between the pre-triheptanoin and triheptanoin treatment periods."( Dietary management and major clinical events in patients with long-chain fatty acid oxidation disorders enrolled in a phase 2 triheptanoin study.
Cataldo, J; Chen, CY; Dwyer, L; Longo, N; Madden, M; Mu, Y; Vockley, J, 2021
)
1.18
"Treatment with triheptanoin-enriched diet reduces ventricular hypertrophy and improves diastolic function in rats with PO, which is associated with enhanced cardiac GO. "( Triheptanoin Alleviates Ventricular Hypertrophy and Improves Myocardial Glucose Oxidation in Rats With Pressure Overload.
Amorim, PA; Doenst, T; Nguyen, TD; Schwarzer, M; Shingu, Y, 2015
)
2.21
"Treatment with triheptanoin resulted in a 90% clinical improvement in non-epileptic paroxysmal manifestations and a normalised brain bioenergetics profile in patients with GLUT1-DS."( Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency.
Adanyeguh, IM; Caillet, S; Gras, D; Hainque, E; Héron, B; Hogrel, JY; Kaphan, E; Mochel, F; Ottolenghi, C; Rinaldi, D; Roubertie, A; Roze, E; Schiffmann, R; Servais, L; Valabregue, R; Vuillaumier, S, 2016
)
2.23
"Treatment with triheptanoin, the triglyceride of heptanoate, is a promising approach to provide alternative fuel to improve oxidative phosphorylation and aid ATP generation."( Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis.
Barkl-Luke, ME; Borges, K; McDonald, TS; Ngo, ST; Tefera, TW; Thomas, NK; Wong, Y, 2016
)
2.22
"Diet treatment with triheptanoin at 30% to 35% of total daily caloric intake was used for all patients."( Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy.
Brunengraber, H; Garritson, BK; Roe, CR; Roe, DS; Wallace, M; Yang, BZ, 2008
)
0.66

Toxicity

ExcerptReferenceRelevance
"Long-chain fatty acid oxidation disorders (LC-FAOD) lead to accumulation of high concentrations of potentially toxic fatty acid intermediates."( UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24weeks of treatment.
Berry, GT; Bowden, A; Burton, B; Cataldo, J; Grunewald, S; Humphrey, R; Kakkis, E; Longo, N; Marsden, DL; Mayhew, J; Murphy, E; Phillips, J; Sanchez-Valle, A; Tanpaiboon, P; Vockley, J; Zhang, L, 2017
)
0.46
" Eighteen patients (62%) had treatment-related adverse events, predominantly gastrointestinal (55%), mild-to-moderate in severity, similar to that seen with prior treatment with medium chain triglyceride (MCT) oil."( UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24weeks of treatment.
Berry, GT; Bowden, A; Burton, B; Cataldo, J; Grunewald, S; Humphrey, R; Kakkis, E; Longo, N; Marsden, DL; Mayhew, J; Murphy, E; Phillips, J; Sanchez-Valle, A; Tanpaiboon, P; Vockley, J; Zhang, L, 2017
)
0.46

Pharmacokinetics

ExcerptReferenceRelevance
" A total of 562 plasma concentrations of heptanoate, the most abundant and pharmacologically active metabolite of triheptanoin, from 13 healthy adult subjects and 30 adult and pediatric subjects with LC-FAOD were included in the population pharmacokinetic (PK) analyses."( Population Pharmacokinetics of Heptanoate in Healthy Subjects and Patients With Long-Chain Fatty Acid Oxidation Disorders Treated With Triheptanoin.
Gosselin, NH; Jomphe, C; Lee, SK; McKeever, K; Putnam, W, 2022
)
1.13

Bioavailability

ExcerptReferenceRelevance
" Blood levels of the odd-chain ketone body beta-hydroxypentanoate confirmed adequate bioavailability of triheptanoin."( Triheptanoin Alleviates Ventricular Hypertrophy and Improves Myocardial Glucose Oxidation in Rats With Pressure Overload.
Amorim, PA; Doenst, T; Nguyen, TD; Schwarzer, M; Shingu, Y, 2015
)
2.07

Dosage Studied

ExcerptRelevanceReference
" Dosing was titrated to 35% of total daily calories over 2 weeks."( A randomized, double-blind trial of triheptanoin for drug-resistant epilepsy in glucose transporter 1 deficiency syndrome.
Auvin, S; Blair, S; Brandabur, M; Collins, A; Davis, R; De Vivo, D; Garcia-Cazorla, A; Horvath, R; Kay Koenig, M; Koutsoukos, T; Lacy, A; Miller, I; Saneto, RP; Scheffer, IE; Striano, P; Tzadok, M, 2022
)
1
"7 hours, supporting a recommended dosing frequency of ≥4 times per day."( Population Pharmacokinetics of Heptanoate in Healthy Subjects and Patients With Long-Chain Fatty Acid Oxidation Disorders Treated With Triheptanoin.
Gosselin, NH; Jomphe, C; Lee, SK; McKeever, K; Putnam, W, 2022
)
0.92
" These results enable the rigorous clinical investigation of triheptanoin in G1D by providing dosing and initial tolerability, safety and ketonemic potential."( Maximum dose, safety, tolerability and ketonemia after triheptanoin in glucose transporter type 1 deficiency (G1D).
Ahn, C; Avila, A; Kallem, RR; Málaga, I; Park, JY; Pascual, JM; Primeaux, S; Putnam, WC; Roe, CR; Shinnar, S, 2023
)
1.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (1 Product(s))

Product Categories

Product CategoryProducts
Beauty & Personal Care1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Derma E Vitamin C No Dark Circles Perfecting Eye Cream -- 0.5 ozDerma EBeauty & Personal Careorange, benzyl acetate, caffeine, citral, vitamin E, decanal, panthenol, provitamin B5, geraniol, vitamin E, glycerin, microcrystalline cellulose, kaolin, linalool, niacinamide, sorbitol, tin oxide, titanium dioxide, triheptanoin2024-11-29 10:47:42

Research

Studies (78)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (5.13)29.6817
2010's47 (60.26)24.3611
2020's27 (34.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.38 (24.57)
Research Supply Index4.58 (2.92)
Research Growth Index5.42 (4.65)
Search Engine Demand Index79.08 (26.88)
Search Engine Supply Index2.15 (0.95)

This Compound (48.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials17 (21.25%)5.53%
Reviews9 (11.25%)6.00%
Case Studies4 (5.00%)4.05%
Observational1 (1.25%)0.25%
Other49 (61.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]